Demographic and clinical manifestations of patients with SLE at enrolment
| N* | ||
|---|---|---|
| Patients, n | 1631 | 1631 |
| Gender, n (%) | ||
| Female | 1458 (89.4) | 1631 |
| Male | 173 (10.6) | |
| Age (years) (mean±SD) | 35.0±13.4 | 1629 |
| Race/ethnicity, n (%) | ||
| Caucasian | 780 (47.9) | 1629 |
| Asian | 264 (16.2) | |
| African | 264 (16.2) | |
| Hispanic | 254 (15.6) | |
| Other | 67 (4.1) | |
| Single/married/other, n (%) | 743 (45.7)/674 (41.4)/210 (12.9) | 1627 |
| Postsecondary education, n (%) | 953 (62.0) (range 32.4–100) | 1536 |
| Disease duration (months) (mean±SD) | 5.6±4.8 | 1631 |
| Number of ACR criteria (mean±SD) | 4.9±1.1 | 1631 |
| Cumulative ACR manifestations, n (%) | 1631 | |
| Malar rash | 589 (36.1) | |
| Discoid rash | 208 (12.8) | |
| Photosensitivity | 585 (35.9) | |
| Oral/nasopharyngeal ulcers | 611 (37.5) | |
| Serositis | 441 (27.0) | |
| Arthritis | 1212 (74.3) | |
| Renal disorder | 441 (27.0) | |
| Neurological disorder | 84 (5.2) | |
| Haematological disorder | 1008 (61.8) | |
| Immunological disorder | 1238 (75.9) | |
| Antinuclear antibody | 1546 (94.8) | |
| SLEDAI-2K score (mean±SD) | 5.3±5.4 | 1616 |
| SLICC/ACR damage index score (mean±SD) | 0.29±0.73 | 620 |
| Medications, n (%) | 1631 | |
| Corticosteroids | 1143 (70.1) | |
| Antimalarials | 1075 (65.9) | |
| Immunosuppressants | 645 (39.6) | |
| ASA | 232 (14.2) | |
| Antidepressants | 164 (10.1) | |
| Warfarin | 87 (5.3) | |
| Anticonvulsants | 75 (4.6) | |
| Antipsychotics | 11 (0.7) | |
| Autoantibodies, n (%) | ||
| Lupus anticoagulant | 237 (21.2) | 1116 |
| Anticardiolipin | 134 (12.5) | 1074 |
| Anti-β2 glycoprotein-I | 155 (14.4) | 1074 |
| Antiribosomal P | 102 (9.6) | 1068 |
| Anti-NR2 glutamate receptor | 126 (12.7) | 996 |
↵* N is the total number of patients with valid data.
ACR, American College of Rheumatology; ASA, acetylsalicylic acid ; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC, Systemic Lupus International Collaborating Clinics.